Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 3

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 3
---
 Therapeutics, Inc., 25 North 38th Street, 11th Floor, Philadelphia, PA 19104.

TABLE OF CONTENTS

| ​ | SUMMARY INFORMATION | ​ |

This summary highlights information contained elsewhere in this Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or the 2024 Annual Report. This summary does not contain all of the information you should consider and we encourage you to read this Proxy Statement and the 2024 Annual Report carefully before voting. 2025 Annual Meeting of Stockholders

Summary of Stockholder Voting Matters

| ​ | ​ | VOTING MATTERS                                                                                              |     | ​ | ​ | FOR MOREINFORMATION | ​ | ​ | BOARD OFDIRECTORSRECOMMENDATION | ​ | ​ |
| ​ | ​ | PROPOSAL 1: Election of Class I Directors for a Three-Year Term Expiring in 2028                            |     | ​ | ​ | Page35              | ​ | ​ | ✓                               
 FOR Each Nominee                
 ​                               | ​ | ​ |
| ​ | ​ | Daphne Quimi                                                                                                
 Carlo Rizzuto, Ph.D.                                                                                        |     | ​ |   |                     |   |   |                                 |   |   |
| ​ | ​ | PROPOSAL 2: Ratification of Appointment of EY as our Independent Registered Public Accounting Firm for 2025 |     | ​ | ​ | Page36              | ​ | ​ | ✓                               
 FOR                             
 ​                               | ​ | ​ |

Our Director Nominees You are being asked to vote on the election of Daphne Quimi and Carlo Rizzuto, Ph.D. as Class I directors, each to serve for a three-year term expiring at our 2028 Annual Meeting of Stockholders. The number of members of our Board of Directors, or the Board, is currently set at eight members and is divided into three classes, each of which has a three-year term. Class I consists of two directors, Class II consists of three directors and Class III consists of three directors. The term of office of our Class I directors expires at the Annual Meeting. We are nominating Daphne Quimi and Carlo Rizzuto, Ph.D. for election at our Annual Meeting to serve until the 2028 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal. Directors are elected